Search Results - "Sigmon, C S"

Predictors of Adherence Among Vulnerable Populations of Adults Assigned to Smoke Very Low Nicotine Content Cigarettes by Morgan, Snell L, Reed, G L, Tidey, J, Bunn, J Y, Harfmann, R F, Heil, S H, Sigmon, S C, Gaalema, D, Higgins, S T

“…Regulators are considering reducing the nicotine content in cigarettes to a minimally addictive level. This could particularly benefit smokers from populations…”
Get full text

Blackhead Disease: Recovery of Layer Flock After Disease Challenge by Sigmon, C S, Malheiros, R D, Anderson, K E, Payne, J A, Beckstead, R B

“…SUMMARY Blackhead disease, caused by the protozoan Histomonas meleagridis, is commonly found in layer pullets raised on the floor. We examined the effects of…”
Get full text

Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study by Sigmon, Stacey C, Dunn, Kelly E, Badger, Gary J, Heil, Sarah H, Higgins, Stephen T

“…Abstract We examined the feasibility of brief outpatient detoxification as a treatment for prescription opioid (PO) abusers. Fifteen PO-dependent adults were…”
Get full text

Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money by SIGMON, Stacey C, TIDEY, Jennifer W, BADGER, Gary J, HIGGINS, Stephen T

“…Psychomotor stimulants often increase cigarette smoking, although the mechanisms responsible for that effect remain unclear. The present study was conducted to…”
Get full text

An injection depot formulation of buprenorphine: extended biodelivery and effects by Sigmon, Stacey C., Moody, David E., Nuwayser, Elie S., Bigelow, George E.

“…ABSTRACT Aim  Buprenorphine is an effective medication for treatment of opioid dependence. An injectable depot formulation of buprenorphine has been developed…”
Get full text

Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification by Sobel, Bai-Fang X, Sigmon, Stacey C, Walsh, Sharon L, Johnson, Rolley E, Liebson, Ira A, Nuwayser, Elie S, Kerrigan, James H, Bigelow, George E

“…Buprenorphine, a partial mu-opioid agonist, has been shown effective for treatment of opioid dependence but also has some abuse potential. A novel formulation…”
Get full text

Evaluation of an injection depot formulation of buprenorphine: placebo comparison by Sigmon, Stacey C., Wong, Conrad J., Chausmer, Allison L., Liebson, Ira A., Bigelow, George E.

“…ABSTRACT Aims  Buprenorphine is a mu‐opioid partial agonist that is marketed in a sublingual formulation as a treatment for opioid dependence. A microcapsule…”
Get full text

Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact by Brooklyn, John R., Sigmon, Stacey C.

“…BACKGROUND:Opioid use disorders (OUDs) are reaching epidemic proportions in the United States, and many geographic areas struggle with a persistent shortage in…”
Get full text

MORPHINE TOLERANCE AS A FUNCTION OF RATIO SCHEDULE: RESPONSE REQUIREMENT OR UNIT PRICE? by Hughes, Christine E., Sigmon, Stacey C., Pitts, Raymond C., Dykstra, Linda A.

“…Key pecking by 3 pigeons was maintained by a multiple fixed‐ratio 10, fixed‐ratio 30, fixed‐ratio 90 schedule of food presentation. Components differed with…”
Get full text

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial by Lofwall, Michelle R, Walsh, Sharon L, Nunes, Edward V, Bailey, Genie L, Sigmon, Stacey C, Kampman, Kyle M, Frost, Michael, Tiberg, Fredrik, Linden, Margareta, Sheldon, Behshad, Oosman, Sonia, Peterson, Stefan, Chen, Michael, Kim, Sonnie

“…Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. To determine whether treatment involving novel weekly and…”
Get more information

Food and Drug Administration approval of sustained‐release buprenorphine for treatment of opioid dependence: realizing its potential by Sigmon, Stacey C., Bigelow, George E.

Get full text

Interim Buprenorphine Treatment During Delays to Comprehensive Treatment: Changes in Psychiatric Symptoms by Streck, Joanna M., Ochalek, Taylor A., Badger, Gary J., Sigmon, Stacey C.

“…Prevalence of depression, anxiety, and mood disorders among individuals with opioid use disorder far exceeds that of the general population. While psychiatric…”
Get full text

A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study by Ochalek, Taylor A., Heil, Sarah H., Higgins, Stephen T., Badger, Gary J., Sigmon, Stacey C.

“…•This sample of adults with opioid use disorder presented with high HIV and HCV risk.•At baseline, deficits in HIV and HCV knowledge were observed.•A mobile…”
Get full text

Use of a low-cost incentive intervention to improve counseling attendance among methadone-maintained patients by Sigmon, Stacey C., Stitzer, Maxine L.

“…Despite the importance of counseling in methadone maintenance treatment, many patients do not take advantage of these services. Incentives for attending group…”
Get full text

Characterizing the Emerging Population of Prescription Opioid Abusers by Sigmon, Stacey C.

“…Despite an alarming recent increase in prescription opioid abuse, the characteristics of prescription opioid abusers remain largely unknown. In this study, the…”
Get full text

Evaluating the utility of the modified cigarette evaluation questionnaire and cigarette purchase task for predicting acute relative reinforcing efficacy of cigarettes varying in nicotine content by Bergeria, Cecilia L., Heil, Sarah H., Davis, Danielle R., Streck, Joanna M., Sigmon, Stacey C., Bunn, Janice Y., Tidey, Jennifer W., Arger, Chris A., Reed, Derek D., Gallagher, Thomas, Hughes, John R., Gaalema, Diann E., Stitzer, Maxine L., Higgins, Stephen T.

“…•Both self-report measures capture relative reinforcing effects.•Subjective effects best predicted concurrent choice self-administration data.•The Cigarette…”
Get full text

Characterizing opioid withdrawal during double-blind buprenorphine detoxification by Dunn, Kelly E, Saulsgiver, Kathryn A, Miller, Mollie E, Nuzzo, Paul A, Sigmon, Stacey C

“…Highlights • Evaluation of withdrawal following 1, 2, or 4-week outpatient buprenorphine taper. • Withdrawal assessed daily using self-reports,…”
Get full text

Feasibility of an Interactive Voice Response System for Daily Monitoring of Illicit Opioid Use During Buprenorphine Treatment by Parker, Maria A, Ochalek, Taylor A, Rose, Gail L, Badger, Gary J, Sigmon, Stacey C

“…In-person retrospective timeline follow-back (TLFB) interviews are a well-established method for collecting self-reports of drug use from patients. However,…”
Get full text

Tobacco Withdrawal Among Opioid-Dependent Smokers by Streck, Joanna M, Heil, Sarah H, Higgins, Stephen T, Bunn, Janice Y, Sigmon, Stacey C

“…Prevalence of cigarette smoking among opioid-dependent individuals is 6-fold that of the general U.S. adult population and their quit rates are notoriously…”
Get full text

Contingent Reinforcement of Marijuana Abstinence Among Individuals With Serious Mental Illness: A Feasibility Study by Sigmon, Stacey C, Steingard, Sandra, Badger, Gary J, Anthony, Stacey L, Higgins, Stephen T

“…The feasibility of using monetary incentives to promote abstinence from marijuana use among individuals with serious mental illness was examined by using a…”
Get full text